Dr. Jeffrey Maxwell Holzbeierlein

Holzbeierlein, Jeffrey M MD



Request an Appointment


Office Locations

Westwood Medical Pavilion and the Richard and Annette Bloch Cancer Care Pavilion 2650 Shawnee Mission Pkwy Level 2-Cancer Center Westwood, KS 66205
The University of Kansas Physicians Medical Office Building 2000 Olathe Blvd MS 3016 Kansas City, KS 66160


Board CertificationUrology


Medical SchoolUniversity of Oklahoma
ResidencyVanderbilt University Medical Center
FellowshipMemorial Sloan Kettering Cancer Center

Clinical Focus

  • Urologic Oncology
  • Kidney Cancer
  • Bladder Cancer
  • Penile Cancer
  • Testicular Cancer
  • Robotic Surgery


  • Bladder Surgery
  • Kidney Surgery
  • Minimally Invasive Surgery
  • Oncological Surgery
  • Oncology
  • Robotic Surgery
  • Second Opinions in Cancer
  • Surgery
  • Urologic Oncology
  • Urological Oncology Surgery
  • Urological Surgery
  • Urology


  • Cystectomy
  • Cystoscopy
  • da Vinci Robotic Procedure-Kidney
  • da Vinci Robotic Surgery
  • Davinci Robotic Procedure-Urology
  • Fluoroscopy
  • Laparoscopic Adrenalectomy
  • Laparoscopic Lymph Node Dissection
  • Laparoscopic Removal-GU Organs
  • Laparoscopic Urological Procedure
  • Laparoscopy
  • Laser Ablation
  • Needle Biopsy
  • Operative Laparoscopy
  • Partial Orchiectomy
  • Prostate Biopsy
  • Prostate Screening
  • Stent Placement
  • Trans Urethral Ultrasound
  • Tumor Ablation
  • Urethroscopy

Conditions Treated

  • Bladder Cancer
  • Cancer
  • Genitourinary Cancer
  • Kidney Cancer
  • Pelvic Masses/Malignancies
  • Penile Cancer
  • Renal Cell Carcinoma
  • Sarcoma
  • Testicular Cancer
  • Ureteral Cancer
  • Urethral Cancer

Personal Statement

Dr. Jeffrey Holzbeierlein is an Associate Professor of Urology at the University of Kansas Medical Center and occupies the John W. Weigel endowed chair of Urology. He joined the faculty after completing his internship and residency at Vanderbilt University and a fellowship in Urologic Oncology at Memorial Sloan Kettering Cancer Center in New York. Dr. Holzbeierlein serves on the Executive Board of the Society of Urologic Oncology and is the past chair of the Young Urologic Oncologists organization. He is a member of the Southwest Oncology Group, the South Central Section of the American Urological Association as well as a fellow of the American College of Surgeons. He is a Diplomate of the Board of Urology. Dr. Holzbeierlein is an assistant editor for the Journal of Urology and is on the editorial board for the American Journal of Urology Review. He reviews for the British Journal of Urology, Urology, Urologic Oncology and Practical Reviews in Urology.

Dr. Holzbeierlein's area of research focuses on the use of a C-terminal inhibitor of heat shock protein 90 for the treatment of prostate cancer for which he is the principle investigator on a DOD New Investigator Award and coinvestigator on an NIH R01 grant. His clinical research interests focus on high risk prostate cancer, bladder cancer, kidney cancer, testicular cancer, sural nerve grafts, and complications of androgen deprivation. He lives in Kansas City with his wife Jill and four children Helen (8), Max (6), Cate (5), and Louisa (2).


  • German